Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms INVENT
- 22 Jan 2025 New trial record
- 15 Jan 2025 According to Synairgen media release, the company have 18 million euro raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections and to support Interim Analysis.